林业发展局批准了Merus的新癌症药物Bizengri,用于治疗先进的胰腺癌和肺癌。 The FDA approved Merus' new cancer drug, Bizengri, for treating advanced pancreatic and lung cancers.
美国食品和药物管理局加速批准Merus的新药Bizengri, 治疗胰腺和肺部的高级NRG1阳性癌症。 The U.S. FDA has granted accelerated approval to Merus' new drug, Bizengri, for treating advanced NRG1-positive cancers in the pancreas and lungs. 对于胰腺癌和非小细胞肺癌,经批准后,该药物是根据eNRGy试验的初步数据批准的,目前正在进行研究以证实其有效性。 Approved for pancreatic adenocarcinoma and non-small cell lung cancer, the drug's approval is based on preliminary data from the eNRGy trial, with ongoing studies to confirm its efficacy. 这是美鲁斯双克隆技术获得FDA的首次批准. This marks the first FDA approval for Merus' Biclonics technology.